Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.52 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.50 |
| ▸ | IGF1R | P08069 | 1/20 | 0.50 |
| ▸ | HRH1 | P35367 | 1/20 | 0.46 |
| ▸ | IDO1 | P14902 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | DRD4 | P21917 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.40 |
| ▸ | CASP1 | P29466 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | AGXT | P21549 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2680220 | 0.98 | CYP1A2 (0.50) | CYP1A2CYP2A6TAAR1ALOX15IGF1R | |
| SCHEMBL7548931 | 0.98 | CYP1A2 (0.50) | CYP1A2CYP2A6TAAR1ALOX15IGF1R | |
| SCHEMBL16744188 | 0.93 | CYP1A2 (0.46) | CYP1A2CYP2A6TAAR1ALOX15IGF1R | |
| SCHEMBL17403329 | 0.93 | IGF1R (0.53) | CYP1A2CYP2A6TAAR1ALOX15IGF1R | |
| SCHEMBL11395796 | 0.91 | IGF1R (0.52) | CYP1A2CYP2A6TAAR1ALOX15IGF1R | |
| SCHEMBL7434377 | 0.87 | CYP1A2 (0.59) | CYP1A2CYP2A6TAAR1ALOX15IGF1R | |
| SCHEMBL7547399 | 0.84 | CYP1A2 (0.56) | CYP1A2CYP2A6TAAR1ALOX15IGF1R | |
| SCHEMBL6546754 | 0.84 | IGF1R (0.64) | CYP1A2CYP2A6TAAR1ALOX15IGF1R | |
| SCHEMBL6546878 | 0.84 | CYP1A2 (0.62) | CYP1A2CYP2A6TAAR1ALOX15IGF1R | |
| SCHEMBL10571160 | 0.81 | IGF1R (0.61) | CYP1A2CYP2A6TAAR1ALOX15IGF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200121684-A1 | MODULATORS OF BTK PROTEOLYSIS AND METHODS OF USE | UNIV YALE (US) | 2020-04-23 | — | — | US | disclosed |
| US-9649373-B2 | Neoseptins: small molecule adjuvants | THE SCRIPPS INSTITUTE (US) | 2017-05-16 | — | — | US | disclosed |
| WO-2017031622-A1 | POLYMERIC CHARGE TRANSFER LAYER AND ORGANIC ELECTRONIC DEVICE CONTAINING SAME | DOW GLOBAL TECHNOLOGIES LLC (US) | 2017-03-02 | — | — | WO | disclosed |
| US-20160000907-A1 | NEOSEPTINS: SMALL MOLECULE ADJUVANTS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-01-07 | — | — | US | disclosed |
| CN-1121376-C | Substituted 4-diarylbutanoic or 5-diarylpentanoic acids and derivatives thereof as matrix metalloproteinase inhibitors | BAYER AG (US) | 2003-09-17 | — | — | CN | disclosed |
| EP-0790974-B1 | SUBSTITUTED 4-BIARYLBUTYRIC OR 5-BIARYLPENTANOIC ACIDS AND DERIVATIVES AS MATRIX METALLOPROTEASE INHIBITIORS | BAYER AG (US) | 2002-08-14 | — | — | EP | disclosed |
| US-6166082-A | Substituted 5-biarylpentanoic acids and derivatives as matrix metalloprotease inhibitors | BAYER CORPORATION (US) | 2000-12-26 | — | — | US | disclosed |
| US-5886024-A | ENZYME INHIBITOR FOR TREATING ARTHRITIS, RHEUMATOID ARTHRITIS, SEPTIC ARTHRITIS, PERIODONTAL DISEASE, CORNEAL ULCERATION, PROTEINURIA, ANEURYSMAL AORTIC DISEASE, DYSTROPHOBIC EPIDERMOLYSIS BULLOSA | BAYER CORPORATION (US) | 1999-03-23 | — | — | US | disclosed |
| US-5886022-A | TREATMENT OF OSTEOARTHRITIS, RHEUMATOID ARTHRITIS, SEPTIC ARTHRITIS, PERIODONTAL DISEASE, CORNEAL ULCERATION, PROTEINURIA, ANEURYSMAL AORTIC DISEASE, DYSTROPHOBIC EPIDERMOLYSIS BULLOSA | BAYER CORPORATION (US) | 1999-03-23 | — | — | US | disclosed |
| US-5886043-A | ANTIARTHRITIC AGENTS, ANTITUMOR AGENTS, ANTIINFLAMMATORY AGENTS | BAYER CORPORATION (US) | 1999-03-23 | — | — | US | disclosed |
| US-5874473-A | OSTEOPOROSIS; ANTIARTHRITIC AGENTS | BAYER CORPORATION (US) | 1999-02-23 | — | — | US | disclosed |
| US-5861428-A | ALLEVIATION OF OSTEOARTHRITIS, RHEUMATOID ARTHRITIS, SEPTIC ARTHRITIS, PERIODONTAL DISEASE, CORNEAL ULCERATION, PROTEINURIA, ANEURYSMAL AORTIC DISEASE, DYSTROPHOBIC EPIDERMOLYSIS BULLOSA, INFLAMMATION, OSTEOPENIAS, TEMPERO | BAYER CORPORATION (US) | 1999-01-19 | — | — | US | disclosed |
| US-5861427-A | ALLEVIATION OF OSTEOARTHRITIS, RHEUMATOID ARTHRITIS, SEPTIC ARTHRITIS, PERIODONTAL DISEASE, CORNEAL ULCERATION, PROTEINURIA, ANEURYSMAL AORTIC DISEASE, DYSTROPHOBIC EPIDERMOLYSIS BULLOSA, CONDITIONS LEADING TO INFLAMMATORY | BAYER HEALTHCARE LLC | 1999-01-19 | — | — | US | disclosed |
| US-5859047-A | ANTIARTHRITIC AGENTS, NERVOUS SYSTEM DISORDERS | BAYER CORPORATION (US) | 1999-01-12 | — | — | US | disclosed |
| US-5854277-A | Thiophenebutanoic acid derivatives as matrix metalloprotease inhibitors | BAYER CORPORATION (US) | 1998-12-29 | — | — | US | disclosed |
| US-5789434-A | ACID, ESTER OR AMIDE DERIVATIVES AS ANTIINFLAMMATORY AGENTS, ANTIARTHRITIC AGENTS AND REDUCTION OF CARTILAGE DETERIORATION | BAYER CORPORATION (US) | 1998-08-04 | — | — | US | disclosed |
| CN-1163604-A | Substituted 4-diarylbutanoic or 5-diarylpentanoic acids and derivatives thereof as matrix metalloproteinase inhibitors | BAYER AG (US) | 1997-10-29 | — | — | CN | disclosed |
| EP-0790974-A1 | SUBSTITUTED 4-BIARYLBUTYRIC OR 5-BIARYLPENTANOIC ACIDS AND DERIVATIVES AS MATRIX METALLOPROTEASE INHIBITIORS | Bayer Corporation (US) | 1997-08-27 | — | — | EP | disclosed |
| WO-1996015096-A1 | SUBSTITUTED 4-BIARYLBUTYRIC OR 5-BIARYLPENTANOIC ACIDS AND DERIVATIVES AS MATRIX METALLOPROTEASE INHIBITIORS | BAYER CORPORATION (US) | 1996-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200121684-A1 | MODULATORS OF BTK PROTEOLYSIS AND METHODS OF USE | BTK, CBL, CRBN | CYP1A2 4629/4885CYP2A6 4582/4885TAAR1 4449/4885 |
| US-20160000907-A1 | NEOSEPTINS: SMALL MOLECULE ADJUVANTS | TLR2, TLR4, TLR1 | CYP1A2 3337/4885CYP2A6 4280/4885TAAR1 1428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.